Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10225810 | 1.00 | ITGA4 (0.77) | ITGA4ITGB1 | |
| SCHEMBL84711 | 0.93 | ITGB1 (0.88) | ITGA4ITGB1 | |
| SCHEMBL10273789 | 0.93 | ITGB1 (0.88) | ITGA4ITGB1 | |
| SCHEMBL92407 | 0.93 | ITGB1 (0.88) | ITGA4ITGB1 | |
| SCHEMBL14771989 | 0.92 | ITGB1 (0.65) | ITGA4ITGB1 | |
| SCHEMBL91569 | 0.92 | ITGA4 (0.77) | ITGA4ITGB1 | |
| SCHEMBL14592451 | 0.89 | ITGA4 (0.90) | ITGA4ITGB1 | |
| SCHEMBL14592463 | 0.89 | ITGA4 (0.90) | ITGA4ITGB1 | |
| SCHEMBL84854 | 0.89 | ITGB1 (0.85) | ITGA4ITGB1 | |
| SCHEMBL85158 | 0.89 | ITGB1 (0.85) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 13/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.